7:50 am Chair’s Opening Remarks

8:00 am Panel Discussion – The Current Landscape of Dry AMD Therapeutics


  • Reviewing complement inhibition as a means of treating dry AMD
  • Outlining the promise of small molecule, cell therapy, stem cell therapy and gene therapy
  • What is the earliest stage of AMD feasible for a clinical trial?

Reviewing the Progression of Dry AMD & Contributing Factors to Better Understand Where Treatment is Effective

8:30 am Identifying Genetic & Systemic Biomarkers for AMD Progression


  • Value of genetics in predicting disease progression
  • Identifying blood serum biomarkers
  • Prediction models for AMD progression

9:00 am Center-Surround Model of AMD Progression – Precision Medicine at Scale

  • Christine Curcio Director of the AMD Histopathology Lab, University of Alabama at Birmingham


  • 15 years of OCT guided anti-VEGF therapy and new histology has shown that AMD is a multilayer disease
  • Soft drusen and subretinal drusenoid deposit – precursors and indicators
  • Macular photoreceptors and clarity of ocular optics allow possible to dissect mechanisms, choose outcome measures, and interpret results from model systems

9:30 am Addressing the Heavy Handling of Retinal Diseases


  • Lipid peroxidation is a major component of retinal pathology
  • Antioxidants cannot mitigate the problem due to stoichiometric reasons
  • Deuterated essential fatty acids offer a new approach

10:00 am Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the dry AMD therapeutic field and establish meaningful business relationships to pursue for the rest of the conference

10:45 am Morning Break

11:15 am Understanding the Complement Pathway to Better Understand the Efficacy When Treating Dry AMD & Geographic Atrophy

  • Dhaval Desai Senior Vice President & Chief Development Officer, IVERIC Bio


  • Providing the scientific significance of targeting the complement pathway
  • Discussing the benefits of targeting complement factors
  • Evaluating patient compliance with treatment duration

11:45 am Pegcetacoplan – Complement C3 Inhibition for GA

  • Ramiro Ribeiro Executive Medical Director & Ophthalmology Program Lead,


  • Discuss different clinical presentations of GA patients
  • Review the role of complement C3 inhibition with pegcetacoplan in GA secondary to AMD
  • Provide an update from the Phase 3 pegcetacoplan clinical studies

12:15 pm Exploring the Gene Delivery of Complement Factor H to Treat Dry AMD


  • Comparing treatment for wet AMD vs. dry AMD
    • Outlining the role of complement system in dry AMD
    • Displaying gene delivery of complement factor H

Discovering the Current Utilization & Next Gen Preclinical Models for Recapitulating the Complexity of Dry AMD to Conduct More Efficacious Preclinical Studies

12:45 pm Panel Discussion – Reviewing the Current State of Dry AMD Preclinical Models & What the Future Looks Like?

  • Hema Ramkumar Oculogenex, Chief Executive Officer
  • Malia Edwards Assistant Professor, Wilmer Eye Institute, John Hopkins
  • Ruchira Singh Associate Professor, Department of Ophthalmology, University of Rochester


  • Brief overview of blue light, sodium iodate and mass cell degranulation models to set the context for this session
  • Discussing the qualities of the ideal preclinical model to identify key areas of development
  • Looking towards the next generation of animal models as for better recapitulation of human dry AMD

1:45 pm Networking Lunch Break

2:45 pm Showcasing C1q Inhibition in Geographic Atrophy Using Light Damage Animal Models

  • Donald Fong Vice President of Ophthalmology, Annexon Bio


  • Classical complement pathway is implicated in geographic atrophy
  • Inhibition of C1q stops the classical complement cascade and provides neuroprotection in light damage animal models
  • Phase 2 clinical trial fully enrolled with results 1st half of 2023

3:15 pm Patient-Derived iPS Cell Model of Macular Degeneration: Disease Mechanisms & Potential Therapeutics

  • Ruchira Singh Associate Professor, Department of Ophthalmology, University of Rochester


  • iPSC models of both AMD and related macular dystrophies recapitulate key maculopathy phenotypes
  • In the iPSC model of multiple maculopathies – perturbation in TIMP3-MMP axis precedes pathological changes
  • Excess TIMP3 and consequently reduced levels of RPE-secreted MMP2 lead to pro-maculopathy cellular changes

Discussing Effective Clinical Trial Design & Diagnosing Endpoints Appropriate for the Complexity of Dry AMD & Geographic Atrophy

3:45 pm Panel Discussion Clinical Trial Design – Lessons Learned & Reflection on Preclinical Work

  • Hemant Khanna Vice President of Preclinical Ocular Research, IVERIC Bio
  • Stephen Poor Director of Translational Biomarkers at NIBR, Novartis
  • Daniel Chao Senior Director & Clinical Lead, Translational Medicine, Janssen


  • What have we learned from the course of clinical trials?
  • Can preclinical trials be better utilized for effective translation into the clinic
  • Contemplating alternatives to BCVA & LLVA

4:15 pm Afternoon Break

4:45 pm Clinical Trial Considerations for Dry AMD

  • Nida Sen Senior Director, Retina Clinical Lead, Janssen


  • How to design effective clinical trials in dry AMD and Geographic Atrophy
  • Understanding disease progression and variability and its impact on clinical trial design
  • How to leverage imaging biomarkers when designing clinical trials for Dry AMD

5:00 pm End of Conference Day Two

5:15 pm Discussing Methodology for Executing Clinical Trials Following Preclinical Findings to Benchmark your Dry AMD Trials

  • Hemant Khanna Vice President of Preclinical Ocular Research, IVERIC Bio


  • What can be learned during preclinical testing to influence the design of clinical trials
  • Reviewing translatability of limited preclinical testing
  • How safety is ensured without appropriate animal models

5:45 pm End of Conference Day One: Chair’s Closing Remarks

5:55 pm Scientific Poster Session


After the formal presentation have finished for the afternoon, the learning and networking carries on. The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships. During this session, scientific posters will be presented on the latest advancements in the dry AMD therapeutic field.

End of Conference Day One